NDAOTICSUSPENSION/DROPS
Approved
Feb 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
5/8 — Partial
CIPRO HC (ciprofloxacin hydrochloride and hydrocortisone) by Novartis is corticosteroid hormone receptor agonists [moa]. Approved for corticosteroid [epc]. First approved in 1998.
Drug data last refreshed 14h ago · AI intelligence enriched 19h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CIPRO HC is a fixed-dose combination of ciprofloxacin (fluoroquinolone antibiotic) and hydrocortisone (corticosteroid) delivered as otic drops for topical ear treatment. It treats acute otitis externa and other ear infections by combining bacterial suppression with anti-inflammatory action. The formulation works via fluoroquinolone DNA gyrase inhibition plus corticosteroid receptor agonism to reduce infection and inflammation simultaneously.
$0.04MPart D
LOE ApproachingDeclining
Mature, declining product with minimal team investment; expect defensive positioning and staff rationalization as LOE approaches.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CIPRO HC offers limited career growth; zero linked job openings reflect a mature, low-spending product in defensive mode. Career value lies in generic defense, channel management, and cost-containment strategy—suitable for early-career professionals developing market access or generic transition expertise, but not ideal for long-term brand building or clinical development.
Brand Manager
Worked on CIPRO HC at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.